Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $9.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors, primarily focusing on the promising preclinical data of Actinium Pharmaceuticals’ ATNM-400. The asset has shown significant potential in various breast cancer models, including those resistant to common treatments like tamoxifen and trastuzumab. This broad anti-tumor activity in large solid tumor indications suggests that ATNM-400 could offer substantial development opportunities once it progresses to clinical trials.
Moreover, ATNM-400’s ability to bind and internalize in resistant breast cancer cells, along with its synergistic effects when combined with trastuzumab in resistant cases, further supports its potential efficacy. These promising results, combined with the company’s solid financial position, contribute to the optimistic outlook and the Buy rating for Actinium Pharmaceuticals.
In another report released on December 12, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.